Pharmacy Perspectives: Optimizing Treatment of Idiopathic Multicentric Castleman Disease

Program Description:

This webinar will include a review of the pathophysiology of iMCD and how it applies to the development of current and emerging treatments. The expert faculty will discuss clinical trial data for current and emerging therapies, with a focus on efficacy, safety, appropriate dosing and formulations, drug-drug interactions, and pandemic-related considerations. Case studies will illustrate how pharmacists can apply evidence-based guideline recommendations to develop patient treatment plans.

Release Date: October 29, 2021
Expiration Date: October 29, 2022
Time to Complete Activity: 1.0 hour


David C. Fajgenbaum, MD, MBA, MSc 
Assistant Professor of Medicine
Division of Translational Medicine and Human Genetics
Associate Director, Patient Impact
Penn Orphan Disease Center
Founding Director
Center for Cytokine Storm Treatment and Laboratory
University of Pennsylvania
Co-Founder and Executive Director
Castleman Disease Collaborative Network
Philadelphia, PA

Ila M. Saunders, PharmD, BCOP
Associate Clinical Professor of Pharmacy
Skaggs School of Pharmacy and Pharmaceutical Sciences
Oncology Clinical Pharmacist, Moores Cancer Center
UC San Diego
La Jolla, CA

This activity is jointly provided by Educational Review Systems, Inc and Paradigm Medical Communications, LLC.

In collaboration with the Castleman Disease Collaborative Network

Target Audience
This activity has been designed to address the educational needs of pharmacists in general, but specifically clinical pharmacists and hematology and oncology pharmacists. It will also benefit other clinicians interested in the management patients with CD.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Review the pathophysiology of iMCD, including similarities and differences among the subtypes such as iMCD-TAFRO and iMCD-NOS
  • Describe the MOAs of iMCD therapies and how they may relate to the pathophysiology of the disease
  • Devise evidence-based, guideline-recommended treatment regimens to optimize outcomes of patients with iMCD


  • Introduction to Castleman Disease
  • Pathophysiology of iMCD
  • Optimizing Treatment of iMCD With Guideline-Recommended Therapies
  • Faculty Panel Discussion
  • Conclusions

Instructions for Participation 
To receive a CPE certificate of participation, you should:

  • Follow instructions to register or log in with your professional information and complete the preactivity assessment
  • View the online activity in its entirety
  • Complete and submit the online posttest and evaluation. You must answer 70% of the posttest questions correctly to earn credit. You will have unlimited opportunities to successfully complete the posttest

A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.

For questions regarding CPE credit, contact the Paradigm CME Department at (845) 398-5949 or

There is no fee required for participation in this activity.


Arrow Shape Facebook Instagram Twitter Youtube Play Arrow Left